Novartis, Qualcomm back trial startup's $6.5M round

Lux Ventures and a joint venture between Novartis and Qualcomm are investing $6.5 million into Science 37, an upstart company that promises to make clinical trials more efficient by uniting stakeholders. Science 37's model relies on partnering with mobile nursing companies, patient advocacy groups and tech outfits to provide its clients with a single point of contact in the study startup phase. The idea is to quickly unite patients and sponsors to eliminate the recruitment delays that often plague clinical trials. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.